Pluripotent stem cells
The use of induced pluripotent stem cells (iPSCs) has garnered attention due to their potential to treat diseases and injuries. The biomanufacturing process of iPSC requires careful control and monitoring for consistency and quality. Key to this process is the use of optimized cell culture media formulations, free from contaminants and adhering to regulatory standards. […]
Monoclonal antibodies
The industry faces the challenge of efficiently producing large quantities of therapeutic proteins to meet growing demand and reduce manufacturing costs. Expectations for mammalian cell production are increasing each year, with efforts focused on enhancing host cells and optimizing cell culture media to achieve high yields, with product titers reaching 10 g/L.Recombinant Insulin is essential […]
Cell-based vaccines
Efforts are being made to shift from traditional egg-based vaccine production to cell-based methods, which offer faster, more stable production, higher yields, and the potential for multiple vaccines in the same platform. Cell culture technology, using various cell lines including HEK293, offers a more flexible, sterile environment for vaccine production, potentially providing better protection than […]
Viral vectors for gene therapy
Viral vectors are the preferred choice for the development of gene therapies, with adeno-associated viruses (AAV), and lentiviruses (LV) being the most adopted systems. Given the increased demand, viral-vector manufacturing requires rapid expansion and standardization across the industry. Diverse manufacturing modalities raise concerns about regulatory standards and quality control, particularly regarding raw materials. Supplementation of […]
